Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Licenses Resolver System to German Proteomics Firm

NEW YORK, Aug. 23 – Rosetta Inpharmatics has licensed its Resolver gene expression data analyzer to functional genomics company Europroteome, Rosetta said on Thursday.

Europroteome, based in Hennigsdorf, Germany, will use the system to help it manage and analyze genomic data for its research in epithelial cancers.

Terms of the agreement were not disclosed.

Earlier this month, Rosetta and Agilent Technologies, which exclusively distributes the Resolver system, said that Germany’s Max Planck Institutes for Molecular Genetics, Infection Biology, and Molecular Plant Physiology would act as European demonstration sites for the Resolver system and for Agilent’s DNA Microarray Scanner.  

Rosetta, based in Kirkland, Wash., also said it has launched a satellite customer service operation in Europe, housed at Agilent Technologies' facility in Amsterdam.  

Bill Buffington, vice president and general manager of Agilent Technologies' life sciences division, said at the time that the deal with the research institutes would “allow greater access to the Rosetta Resolver system and Agilent's new open-systems-based DNA Microarray Scanner for prospective users in Europe.”

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.